Ocular Therapeutix, Inc. (OCUL)
NASDAQ: OCUL · Real-Time Price · USD
7.11
+0.71 (11.01%)
At close: Apr 11, 2025, 4:00 PM
7.02
-0.09 (-1.22%)
After-hours: Apr 11, 2025, 7:44 PM EDT
Ocular Therapeutix Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for Ocular Therapeutix stock have an average target of 16.22, with a low estimate of 11 and a high estimate of 22. The average target predicts an increase of 128.13% from the current stock price of 7.11.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Ocular Therapeutix stock from 10 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 5 | 5 | 5 | 5 | 6 | 7 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 9 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| William Blair | William Blair | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Apr 8, 2025 |
| Needham | Needham | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +110.97% | Apr 8, 2025 |
| RBC Capital | RBC Capital | Buy Initiates $17 | Buy | Initiates | $17 | +139.10% | Mar 18, 2025 |
| Needham | Needham | Strong Buy Initiates $15 | Strong Buy | Initiates | $15 | +110.97% | Mar 11, 2025 |
| Citizens Capital Markets | Citizens Capital Markets | Buy Maintains $22 → $19 | Buy | Maintains | $22 → $19 | +167.23% | Mar 4, 2025 |
Financial Forecast
Revenue This Year
72.39M
from 63.72M
Increased by 13.59%
Revenue Next Year
82.43M
from 72.39M
Increased by 13.88%
EPS This Year
-1.24
from -1.22
EPS Next Year
-1.31
from -1.24
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 83.1M | 105.0M | 219.1M | ||
| Avg | 72.4M | 82.4M | 151.8M | ||
| Low | 65.4M | 67.3M | 81.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 30.3% | 45.1% | 165.8% | ||
| Avg | 13.6% | 13.9% | 84.1% | ||
| Low | 2.6% | -7.0% | -0.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.10 | -1.18 | -0.08 | ||
| Avg | -1.24 | -1.31 | -1.04 | ||
| Low | -1.32 | -1.40 | -1.73 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.